Table 1.
Baseline parameters of patients with cardiac amyloidosis and hypertrophic cardiomyopathy. Comparison to healthy control subjects.
| CTRL | HCM | CA | Post-Hoc Test p-Value |
|
|---|---|---|---|---|
| N | 44 | 20 | 43 | |
| Sex [males] | 23 | 10 | 32 | |
| Age [yrs] b | 56.3 (52.5; 62.9) a | 63.9 ± 7.4 | 79 (71; 85) a | CA-HCM, p < 0.001 CA-CTRL, p < 0.001 HCM-CTRL, p = 0.005 |
| BSA [m²] c | 1.87 ± 0.20 | 1.96 ± 0.18 | 1.89 ± 0.22 | n.s. |
| HR [bpm] b | 64.9 ± 10.0 | 63.1 ± 7.8 | 74.0 ± 14.8 | CA-HCM; p = 0.001 CA-CTRL; p = 0.004 HCM-CTRL; p = 0.706 |
| LV-EF [%] b | 66.9 ± 4.7 | 72.2 ± 8.6 | 60.0 (50; 65) a | CA-HCM; p < 0.001 CA-CTRL; p < 0.001 HCM-CTRL; p = 0.043 |
a median value (interquartile range), b ANOVA–Welch; Games–Howell, c ANOVA–Tukey–HSDCTRL—healthy control subjects, HCM—hypertrophic cardiomyopathy patients, CA—cardiac amyloidosis patients, BSA—body surface area, HR—heart rate, LV—left ventricular, EF—ejection fraction, n.s.—not significant.